Endorsements

Dr. Christophe Fournier, MSF’s International Council President, February 2009
"We have patients suffering from diseases such as sleeping sickness who are forced to endure toxic and dangerous treatments just to have a limited chance at survival; at the same time, treatments for those living with visceral leishmaniasis remain prohibitively expensive, and treatments for chronic Chagas patients are nonexistent. DNDi has demonstrated through its work how innovative, needs-driven collaborative R&D can produce medicine adapted to our patients."


Yves Ribeill, Scynexis President & CEO, December 2008
"Scynexis believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases. We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness."


Leire Pajín, Spanish Secretary of International Cooperation, March 2008
"To fight against neglected diseases is to put a voice where there is only silence, and a light in the darkness. It is an ethic responsibility of the governments in developed countries. … We cannot carry on allowing the lack of a solid and continuous international response to fight against neglected diseases."


Dr. Regina Rabinovich, Director of Infectious Diseases Development, Bill & Melinda Gates Foundation, December 2007
"Far too little R&D is devoted to neglected diseases such as trypanosomiasis and visceral leishmaniasis, which threaten millions of people in the developing world but are virtually unheard of in rich countries. By helping to close this research gap, DNDi is bringing us closer to the day when the word ‘neglected’ no longer applies to these diseases."


Dr. Federico M Gomez de las Heras, Vice President of the Infectious Diseases Center of Excellence in Drug Discovery (ID CEDD) at GSK., June 2007
"We hope this and similar alliances serve as a model for future drug development for neglected diseases.”


Jean Michel Severino, Directeur général, Agence
Française de Développement (AFD), juin 2006
"L'engagement de l'AFD auprès du DNDi traduit notre volonté de soutenir des initiatives innovantes, basées sur les partenariats public/privé, qui visent non seulement à apporter une réponse aux besoins de populations de pays en développement qui souffrent de l'absence de traitements adaptés, mais aussi à renforcer les capacités technologiques et les savoirs faire des pays du Sud."